Mercury Biomedical* (6932) signed a material transfer agreement (MTA) with the international API company Taiwan Shenlong (1789). The two parties cooperated to use Mercury Biomedical*’s StackdoseTMThe new drug technology development platform develops the main ingredients of specific drugs. The drug developed this time is an anti-tumor drug that contains DNA components required to inhibit cell growth. Once the early development is successful, it can be accurately licensed with foreign pharmaceutical companies, and Drug development using this API can begin directly from phase II clinical trials.
The drug jointly developed by Mercury Biomedical* and Taiwan Shenlong is an anti-tumor drug that utilizes DNA components required to inhibit cell growth. It is currently in injection form and is used for the treatment of colorectal cancer. Using StackdoseTMThe platform conducts a specific powder stacking and coating process to develop oral tablets, trying to reduce gastric acid damage and control the increase in the absorption rate of the drug at specific locations in the duodenum to increase the oral bioavailability of the drug. It is also trying to use special oral packaging. This will reduce the side effects of current injections. In the future, in addition to the treatment of colorectal cancer, it will also be used in the treatment of small cell lung cancer and pancreatic cancer.
According to statistics from the World Health Organization (WHO), colorectal cancer is the third most common cancer in the world, accounting for approximately 10% of all cancer cases, and is also the second leading cause of cancer death in the world. According to the Colorectal Cancer Drugs Global Market Report 2023 released by The Business Research Company, the global market size of colorectal cancer drugs is estimated to reach approximately US$14.21 billion in 2023, and is expected to grow by 2027. to US$16.22 billion, a compound annual growth rate of 3.3%. The active pharmaceutical ingredient (API) developed by Mercury Biomedical* and Taiwan Shenlong this time has improved the dosage form, controlled drug absorption at precise sites, and tried to reduce side effects, hoping to provide patients with better medication choices. In the future, this drug will also be developed and applied to unmet medical needs such as small cell lung cancer and pancreatic cancer.
Taiwan Sinon mainly supplies the international API market, with anti-cancer drugs as the bulk. Its global customers include top international patent pharmaceutical companies and the world’s top ten famous pharmaceutical manufacturers. Mercury Biomedical* signed an MTA with Taiwan Shenlong, not only to enter the development of cancer drugs, but also to accurately connect with international pharmaceutical companies. It is expected that the advantages of both parties will be used in the future to jointly develop more active pharmaceutical ingredients (APIs).
Stackdose by Mercury Biomedical*TMThe technology platform is based on the pharmaceutical process of 3D powder printing and combined with the exclusive drug binding formula to develop new dosage forms of tablets with controllable time dissolution and precise site absorption, and improve the bioavailability of active pharmaceutical ingredients (APIs) for optimal performance. effect, thereby reducing drug dosage and thereby reducing side effects. StackdoseTMThe 3D powder stacking of the technology platform is a closed machine that combines powder supply, dust collection, cleaning and sieving into one machine to avoid dust generation and contamination of the production environment, making it easier to manufacture poisonous drugs and integrating them into one machine. Contributes to the development and manufacturing of cancer APIs.
This article does not represent the position of MoneyDJ and is for reference only. It does not constitute an offer, solicitation or invitation, inducement, representation of any kind or form, or the establishment of any suggestions and recommendations. Readers are advised to use their independent thinking skills and make their own investments. It has been decided that Jingjing Financial Media will not be involved if any losses are incurred due to relevant suggestions.
Data source-MoneyDJ Financial Management Network